X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement will support Convergent's pipeline of next-generation radiotherapies including its lead asset, CONV01-α (225Ac−Rosopatamab), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to Ac-225.
Lead Product(s): 225Ac−rosopatamab,177Lu-PSMA-I&T,68Ga-PSMA-11
Therapeutic Area: Oncology Product Name: CONV01-alpha
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Convergent Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 25, 2022
Details:
Astatine-211 is a high-energy alpha-emitting radioisotope that can have a very powerful therapeutic effect when combined with the right targeting molecule. PMI is developing an astatine-211 labeled inhibitor of prostate-specific membrane antigen (PSMA) known as PMI21.
Lead Product(s): PMI21
Therapeutic Area: Oncology Product Name: PMI21
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Precision Molecular
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 26, 2022
Details:
PDS Biotechnology licenses National Cancer Institute for intellectual property related to tumor-associated active T-cell receptor gamma. The administration of PDS0102, Versamune-TARP tumor antigen combination, led to induction of large numbers of tumor targeted killer T-cells.
Lead Product(s): PNT2001,Actinium-225
Therapeutic Area: Oncology Product Name: PNT2001
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Point Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
